Gyre Therapeutics Q4 2024 Earnings Report

Gyre Therapeutics EPS Results

• Actual EPS: $0.01
• Consensus EPS: $0.04
• Beat/Miss: Missed by -$0.03
• One Year Ago EPS: N/A

Gyre Therapeutics Revenue Results

• Actual Revenue: $27.87 million
• Expected Revenue: $23.50 million
• Beat/Miss: Beat by +$4.37 million
• YoY Revenue Growth: N/A

Gyre Therapeutics Announcement Details

• Quarter: Q4 2024
• Date: 3/17/2025
• Time: Before Market Opens
• Conference Call Date: Monday, March 17, 2025
• Conference Call Time: 9:30AM ET

Gyre Therapeutics (NASDAQ:GYRE) (NASDAQ: GYRE) is a clinical-stage biotechnology company focused on expanding the druggable proteome by targeting disease-associated proteoforms. Headquartered in Cambridge, Massachusetts, the company has built a proprietary discovery platform that integrates high-resolution mass spectrometry, single-cell proteomics and machine-learning analytics to map protein isoforms linked to human disease. By illuminating previously undruggable proteoforms, Gyre seeks to develop small-molecule and biologic therapies across a range of conditions with high unmet need.

The company’s lead pipeline entries target metabolic and fibrotic disorders, with a preclinical program aimed at modulating key proteoforms implicated in non-alcoholic steatohepatitis (NASH) and a discovery project addressing cardiovascular risk through selective proteoform engagement. Gyre’s scientists leverage structure-based design and phenotypic screening to optimize compounds for potency, selectivity and tissue specificity, advancing candidates toward clinical development.

At the core of Gyre’s approach is its Proteoform Intelligence™ platform, which couples advanced proteomics workflows with deep learning to uncover proteoform signatures that drive pathology. This capability enables the rapid identification of novel targets and accelerates medicinal chemistry campaigns by revealing unique binding pockets and functional hotspots. Gyre also collaborates with leading academic institutions and pharmaceutical partners to expand its target space and validate proteoform-based hypotheses in disease models.

Founded in 2019 by a team of proteomics and drug discovery experts, Gyre Therapeutics is led by CEO Dr. Benjamin Levy, whose background spans roles in biotech venture investing and translational research. The leadership team includes seasoned executives in chemistry, biology and clinical development, reflecting a commitment to building a fully integrated organization. As Gyre advances toward first-in-human studies, the company aims to pioneer a new class of precision therapies grounded in the modulation of proteoforms.